PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy
A study has described the preparation of the novel AST-SSLNs, which a stealth lipid nanoparticles loaded with AST, to improve the bioavailability of AST, revealing a great potential of AST as a potent natural antioxidant and a novel therapy for AD
The results were significant: At 48 weeks, participants receiving the 12 mg dose achieved a mean weight reduction of 24.2% (approximately 58 pounds or 26.2 kg) 100% of participants on the 8 mg or 12 mg doses lost at least 5% of their body weight More than 90% of participants on the 12 mg dose lost at least 10% of their body weight Nearly half of participants on the highest dose lost 25% or more of their body weight The study also showed improvements in cardiometabolic markers including blood pressure, triglycerides, LDL cholesterol, and fasting glucose
With microinfusion delivery, the effect amplifies
Supplements are not miracle cures or quick fixes for complex chronic conditions
Short culture period
